LOS ANGELES - A trial court did not err in refusing to instruct the jury in the California bellwether PPA state court trial that compliance with Food and Drug Administration standards is not a basis for assessing a design defect and for allowing the defense to challenge the findings of an epidemiological study on the recalled drug, the Second District Court of Appeal ruled Feb. 27 (Pearl O'Neill, et al. v. Novartis Consumer Health, No. B174512, Calif. App., 2nd Dist.; See February 2004, Page 4).
Full story on lexis.com
Link
- posted by Hernan at 10:00 PM
Post a Comment
<< Home